Novo Nordisk, a Danish pharma group, has named Pinder Sahota as its new general manager and corporate vice president, UK, it was reported yesterday.
Sahota, who brings experience from business, commercial and leadership roles to Novo, was most recently responsible for creating commercial and market development strategies across Europe as senior vice president of market and commercial development for Europe at Smith & Nephew.
He began his pharmaceutical career in sales and marketing with companies that formed Sanofi Aventis, then moved to SmithKline Beecham, now GlaxoSmithKline, where he held a number of commercial leadership roles including vice president of commercial operations of diabetes and cardiovascular. In 2009 Sahota moved to AstraZeneca to take up the role of vice president for primary care in the UK, and was in that position until moving to the role of managing director for the UK and Ireland for Smith & Nephew in 2013.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults